Metabolic Activity of Normal Glandular Tissue on $^{18}$F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: Correlation with Menstrual Cycles and Parenchymal Enhancements

Young-Sil An, Yongsik Jung, Ji Young Kim, Sehwan Han, Doo Kyoung Kang, Seon Young Park, Tae Hee Kim

Departments of Nuclear Medicine and Molecular Imaging, Surgery, and Radiology, Ajou University School of Medicine, Suwon, Korea

**Purpose:** The aims of our study were to correlate the degree of metabolic activity in normal glandular tissue measured on $^{18}$F-fluorodeoxyglucose positron emission tomography/computed tomography ($^{18}$F-FDG PET/CT) with qualitative background parenchymal enhancement (BPE) grades on magnetic resonance imaging (MRI), and to investigate the change in standardized uptake value (SUV) according to the patients' menstrual cycles.

**Methods:** From January 2013 to December 2015, 298 consecutive premenopausal patients with breast cancer who underwent both breast MRI and $^{18}$F-FDG PET/CT were identified. BPE was evaluated in the contralateral breast of cancer patients and categorized as minimal, mild, moderate, or marked based on Breast Imaging Reporting and Data System criteria. We analyzed the correlation between BPE and maximum SUV (SUVmax) and mean SUV (SUVmean) values. We also analyzed the metabolic activity of normal glandular tissue according to the patients' menstrual cycles.

**Results:** The mean SUVmax and SUVmean values differed significantly according to the patients' menstrual cycles, with the highest values in the 3rd week and the lowest value in the 2nd week. Of 29 patients with low metabolic parenchyma (high BPE but low SUVmean values), 17 (58.6%) were in the 4th week of their menstrual cycle.

**Conclusion:** The metabolic activity of normal breast parenchyma, which is highest in the 3rd week and lowest in the 2nd week of the menstrual cycle, correlates moderately with BPE on MRI. Metabolic activity tends to be lower than blood flow and vessel permeability in the 4th week of the menstrual cycle.

**Key Words:** Magnetic resonance imaging, Menstrual cycle, Metabolism, Positron Emission Tomography, Computed Tomography

**INTRODUCTION**

Genetic mutations (including BRCA1 and BRCA2), family history, and the use of estrogen plus progesterin are well known risk factors for breast cancer development [1-5]. Additionally, mammographic breast density is an independent risk factor for breast cancer, increasing three to six times in patients with dense compared to fatty breasts [6-11].

Background parenchymal enhancement (BPE) depends on tissue vascularity and contrast agent permeability, and may be affected by endogenous hormones and hormone replacement therapies. Recent studies have reported that BPE on magnetic resonance imaging (MRI) is a significant risk factor for breast cancer [12,13].

There are many studies reporting the clinical implications of BPE, associated with recurrence-free survival and patients' outcomes [14,15]. High parenchymal enhancement around tumors is associated with worse ipsilateral breast cancer recurrence-free survival in patients following breast-conserving surgery for ductal carcinoma in situ (DCIS) [16]. BPE decreases after neoadjuvant chemotherapy, and the degree of BPE reduction correlates with tumor response [17] and recurrence-free survival after neoadjuvant chemotherapy [18]. Compared to minimal or mild BPE, moderate or marked BPE causes inaccurate estimation of cancer extent [19], along with more frequent positive resection margins, after breast-con-
serving surgery [20].

Positron emission tomography/computed tomography (PET/CT) using the radiotracer \(^{18}\)F-fluorodeoxyglucose (\(^{18}\)F-FDG) enables imaging of the metabolic activity of breast tissue, whilst BPE reflects tissue vascularity and vessel permeability. There are few studies reporting the imaging findings of \(^{18}\)F-FDG PET/CT in normal breast parenchyma [21,22]. The metabolic activity of normal breast parenchyma could provide a susceptible microenvironment for cancer development. It is intuitive that increased vascularity and vessel permeability are important for increased FDG uptake in normal glandular tissues. However, in previous studies, only moderate correlations were observed between BPE and FDG uptake [21,22].

Therefore, the purposes of our study were to investigate the degree of glucose metabolism in the normal breast parenchyma of patients with breast cancer, in order to correlate the degree of standardized uptake value (SUV) uptake with qualitative BPE values on MRI, and to investigate changes in SUV uptake in accordance with the menstrual cycle.

**METHODS**

**Patients**

This retrospective study was approved by Ajou University Hospital Institutional Review Board (AJIRB-MED-MDB-17-230). Neither patient approval nor informed consent were required for the review of medical records or images.

From January 2013 to December 2015, 1,087 consecutive patients newly diagnosed with breast cancer underwent breast MRI in our hospital. Of the 1,087 patients, we excluded 515 postmenopausal patients, 144 patients who underwent \(^{18}\)F-FDG PET/CT more than 4 days after MRI or did not undergo initial \(^{18}\)F-FDG PET/CT, 11 patients with bilateral breast cancer, and 119 patients who did not know their last normal menstrual period or who had extremely irregular menstrual cycles. Finally, we included 298 premenopausal patients newly diagnosed with breast cancer, who underwent both breast MRI and \(^{18}\)F-FDG PET/CT, and who knew their last normal menstrual period. The mean time interval between breast MRI and \(^{18}\)F-FDG PET/CT was 2 days. The mean age of 298 patients was 43 years (43 ± 6 years). Histopathologic results included: invasive ductal carcinoma, not otherwise specified (\(n = 232\)), DCIS (\(n = 16\)), invasive lobular carcinoma (\(n = 21\)), mucinous carcinoma (\(n = 15\)), metaplastic carcinoma (\(n = 4\)), tubular carcinoma (\(n = 3\)), invasive micropapillary carcinoma (\(n = 6\)), and invasive cribriform carcinoma (\(n = 1\)). Histologic and nuclear grade data were not available in six patients, and hormone receptor and human epidermal growth factor receptor 2 (HER2) data were not available in three patients. Of the 298 patients, 220 underwent surgery after initial diagnosis, and 78 underwent neoadjuvant chemotherapy after MRI.

**Magnetic resonance imaging acquisition**

Breast MRI was performed with patients in the prone position using a 1.5T magnet (SignaHDxt; GE Healthcare, Milwaukee, USA) with an 8-channel array breast coil.

The imaging sequence included a fat-suppressed axial T2-weighted sequence (repetition time [TR] = 3,500–4,000 ms; echo time [TE] = 98–108 ms; flip angle of 90°; matrix = 320 × 256; field of view [FOV] = 320 × 320 mm; slice thickness = 3 mm) and axial T1-weighted fat suppressed three-dimensional (3D) volumetric scan (TR = 5.1 ms; TE = 2.4 ms; flip angle of 10°; matrix = 300 × 300; FOV = 300 × 300 mm; slice thickness = 1.5 mm; phase acquisition time = 90 seconds) that was obtained before and at five time points after intravenous injection of 0.1 mmol/L gadolinium chelate/kg body weight (Gadovist; Bayer Schering Pharma, Berlin, Germany). After the examination, postprocessing was performed including subtraction images and maximum intensity projection images.

**\(^{18}\)F-fluorodeoxyglucose positron emission tomography/computed tomography examination**

Whole-body \(^{18}\)F-FDG PET/CT was performed in the supine position on a Discovery ST scanner (GE Healthcare). Patients fasted for at least 6 hours before each received 5 MBq/kg of FDG intravenously with a blood glucose level < 150 mg/dL. Non-enhanced, low-dose CT scans were obtained from the base of the skull to the upper thigh (120 kV, 30–100 mA in the Automa mode, section width = 3.75 mm). After CT scanning, seven or eight frames (3 minutes/frame) of emission PET data were acquired in the 3D mode. PET images were re-constructed using an iterative method (ordered-subsets expectation maximization with two iterations and 20 subsets; FOV = 600 mm; slice thickness = 3.27 mm) with attenuation correction using nonenhanced CT.

**Image analysis**

For MRI analysis, two breast radiologists with 8 and 15 years of experience in breast imaging reviewed the MR images in consensus. BPE was evaluated in the contralateral breast of cancer patients and categorized as minimal, mild, moderate, or marked based on Breast Imaging Reporting and Data System (BI-RADS) criteria [23]. A combination of contrast-enhanced images at 90 seconds, subtraction, and maximum-intensity projection images were used to analyze BPE.

For PET/CT analysis, a specialist in nuclear medicine with 11 years of PET experience reviewed \(^{18}\)FDG PET/CT images.
on a dedicated workstation (GE Advantage Workstation 4.4; GE Healthcare). The volumetric region of interest was carefully placed in the whole glandular tissue of the contralateral normal breast. The SUVmax and SUVmean values of normal glandular tissue were calculated automatically. All SUVs were estimated based on injected dose and body weight. Patients who had minimal BPE and SUVmean values of more than 1.0 were classified as the high metabolic group, patients who had moderate or marked BPE and SUVmean values of less than 1.0 were classified as the low metabolic group, and others were classified as the average metabolic group. We compared the clinical and pathologic characteristics of these groups.

**Histopathological data**

Surgical specimens were evaluated according to the following histopathologic features: tumor size, histological type of carcinoma, Black nuclear grade (grade 1, poorly differentiated; grade 2, moderately differentiated; grade 3, well differentiated), modified Bloom-Richardson histological grade (grade 1, well differentiated; grade 2, moderately differentiated; grade 3, poorly differentiated), and expression of estrogen receptor (ER), progesterone receptor (PR), and HER2. ER and PR positivity were determined using a cutoff value of 10% positively stained nuclei. Tumors with HER2 scores of 3+ were considered positive. In tumors with a 2+ score, gene amplification by fluorescence in situ hybridization was used to determine HER2 status. For dichotomous analysis, nuclear grade was classified as high (grade 1) or low (grades 2 and 3), and histologic grade as low (grade 1 and 2) or high (grade 3).

**Statistical analysis**

We used independent t-tests to compare mean SUVmax and SUVmean values according to the dichotomized BPE group. One-way analysis of variance and post hoc Tukey range tests were used to compare mean SUVmax and SUVmean values according to the qualitative BPE grades and patients’ menstrual cycles. Spearman’s correlation coefficients were calculated to evaluate the correlation between BPE grade and SUVmax or SUVmean. A correlation coefficient of 0.00 to 0.39 was considered weak, 0.40 to 0.59 moderate, 0.60 to 0.79 strong, and 0.80 to 1.00 very strong. To compare the clinical and pathological data between patients with high and low metabolic parenchyma, independent t-tests, chi-square tests, and Fisher exact tests were used.

All analyses were performed using the SPSS version 23.0 statistical software package (IBM Corp., Armonk, USA), with a value of \( p < 0.05 \) considered statistically significant.

**RESULTS**

The mean SUVmax and SUVmean values according to four qualitative BPE grades are summarized in Table 1 and Figure 1. The mean ± standard deviation (SD) SUVmax values differed significantly \( (p < 0.001) \) across the minimal \( (1.42 ± 0.34) \), mild \( (1.59 ± 0.47) \), moderate \( (1.82 ± 0.40) \), and marked \( (2.06 ± 0.31) \) groups; post hoc analyses revealed statistically significant differences between the minimal and moderate \( (p < 0.001) \), minimal and marked \( (p < 0.001) \), mild and marked \( (p < 0.001) \), and moderate and marked \( (p = 0.026) \) groups, but not between the minimal and mild groups \( (p = 0.065) \).

The mean ± SD SUVmean values differed significant \( (p < 0.001) \) across the minimal \( (0.87 ± 0.21) \), mild \( (0.97 ± 0.21) \), moderate \( (1.14 ± 0.25) \), and marked \( (1.32 ± 0.21) \) groups; post hoc analyses revealed statistically significant differences between the minimal and moderate \( (p < 0.001) \), minimal and marked \( (p < 0.001) \), mild and moderate \( (p < 0.001) \), mild and marked \( (p < 0.001) \) and moderate and marked \( (p = 0.001) \) groups, but not between the minimal and mild groups \( (p =

**Table 1.** Comparison of average of SUVmax and SUVmean according to the qualitative BPE grade

| SUV    | Minimal (n=52) | Mild (n=86) | Moderate (n=133) | Marked (n=27) | P-value   |
|--------|----------------|-------------|------------------|---------------|-----------|
| SUVmax | 1.42± 0.34     | 1.59± 0.47  | 1.82± 0.40       | 2.06± 0.31    | <0.001    |
| SUVmean| 0.87± 0.21     | 0.97± 0.21  | 1.14± 0.25       | 1.32± 0.21    | <0.001    |

Data are presented as mean± SD. SUV= standardized uptake value; BPE= background parenchymal enhancement.

**Figure 1.** Mean values of maximum standardized uptake value (SUVmax) and SUVmean according to the background parenchymal enhancement (BPE) grade on magnetic resonance imaging.
Spearman’s correlation coefficients revealed moderate significant correlations between BPE grade and SUVmax (r = 0.472, p < 0.001) and BPE grade and SUVmean (r = 0.498, p < 0.001).

The mean SUVmax and SUVmean values according to the menstrual cycle are summarized in Table 2 and Figure 2. The mean ± SD SUVmax values differed significantly (p = 0.011) across the 1st (1.68 ± 0.37), 2nd (1.56 ± 0.37), 3rd (1.81 ± 0.48), and 4th (1.74 ± 0.50) weeks; post hoc analyses revealed statistically significant differences between the 2nd and 3rd weeks (p = 0.007). The mean ± SD SUVmean values differed significantly (p = 0.006) across the 1st (1.05 ± 0.23), 2nd (0.96 ± 0.23), 3rd (1.12 ± 0.31), and 4th (1.08 ± 0.26) weeks; post hoc analyses revealed statistically significant differences between the 2nd and 3rd (p = 0.003) and 2nd and 4th weeks (p = 0.045).

Table 2. The mean values of SUVmax and SUVmean according to the menstrual cycle

| SUV       | 1st week (n=80) | 2nd week (n=62) | 3rd week (n=70) | 4th week (n=86) | p-value |
|-----------|----------------|----------------|----------------|----------------|---------|
| SUVmax    | 1.68 ± 0.37    | 1.56 ± 0.37    | 1.81 ± 0.48    | 1.74 ± 0.50    | 0.011   |
| SUVmean   | 1.05 ± 0.23    | 0.96 ± 0.22    | 1.12 ± 0.31    | 1.08 ± 0.26    | 0.006   |

Data are presented as mean ± SD.

SUV = standardized uptake value.

Table 3. Comparison of clinical and pathologic factors between patients with high, low, and average metabolic parenchyma

| Characteristic            | High metabolic parenchyma (n=22) | Low metabolic parenchyma (n=29) | Average metabolic parenchyma (n=247) | p-value* | p-value† |
|---------------------------|----------------------------------|---------------------------------|--------------------------------------|----------|----------|
| Age (yr)                  | 40 ± 8                           | 44 ± 5                          | 43 ± 6                               | 0.043    | 0.064    |
| Height (cm)               | 160.14 ± 6.10                    | 159.48 ± 5.24                   | 159.32 ± 4.99                        | 0.683    | 0.767    |
| Weight (kg)               | 58.87 ± 8.24                     | 60.64 ± 9.00                    | 57.95 ± 8.68                         | 0.728    | 0.273    |
| BMI (kg/m²)               | 23.06 ± 3.83                     | 23.81 ± 3.06                    | 22.84 ± 3.17                         | 0.439    | 0.305    |
| Histologic grade          |                                  |                                 |                                      | 0.793    | 0.865    |
| Low                       | 13 (7.1)                         | 17 (9.3)                        | 152 (83.5)                           |          |          |
| High                      | 9 (8.2)                          | 12 (10.9)                       | 89 (80.9)                            |          |          |
| Nuclear grade             |                                  |                                 |                                      | 0.903    | 0.468    |
| Low                       | 11 (8.6)                         | 14 (8.4)                        | 141 (84.9)                           |          |          |
| High                      | 11 (8.7)                         | 15 (11.9)                       | 100 (79.4)                           |          |          |
| Estrogen receptor         |                                  |                                 |                                      | 0.286    | 0.416    |
| Positive                  | 15 (6.6)                         | 25 (11.0)                       | 187 (82.4)                           |          |          |
| Negative                  | 6 (8.6)                          | 4 (6.0)                         | 57 (85.1)                            |          |          |
| Progesterone receptor     |                                  |                                 |                                      | 0.574    | 0.844    |
| Positive                  | 16 (7.6)                         | 20 (9.5)                        | 174 (82.9)                           |          |          |
| Negative                  | 5 (5.8)                          | 9 (10.7)                        | 70 (33.3)                            |          |          |
| HER2                      |                                  |                                 |                                      | 0.320    | 0.247    |
| Positive                  | 6 (12.2)                         | 5 (10.2)                        | 38 (77.6)                            |          |          |
| Negative                  | 14 (5.7)                         | 24 (9.8)                        | 206 (84.4)                           |          |          |
| Menstrual cycle           |                                  |                                 |                                      | 0.002    | 0.001    |
| 1st week                  | 8 (10.0)                         | 4 (5.0)                         | 68 (85.0)                            |          |          |
| 2nd week                  | 9 (14.5)                         | 5 (8.1)                         | 48 (77.4)                            |          |          |
| 3rd week                  | 3 (4.3)                          | 3 (4.3)                         | 64 (91.4)                            |          |          |
| 4th week                  | 2 (2.3)                          | 17 (19.8)                       | 67 (77.9)                            |          |          |

Data are presented as mean ± SD or number (%).

BMI = body mass index; HER2 = human epidermal growth factor receptor 2.

*Between patients with high and low metabolic parenchyma; †Between patients with high, low, and average metabolic parenchyma.
Comparisons between patients with high, low, and average metabolic parenchyma (Table 3) revealed significantly different mean ± SD ages between those with high and low metabolic parenchyma (40 years vs. 44 years, respectively, \( p = 0.043 \)). Significant differences were observed in the menstrual cycles of patients with high versus low metabolic parenchyma (\( p = 0.002 \)) and patients from all three groups (\( p = 0.001 \)); the 4th week of the menstrual cycle was more frequently observed in the low metabolic group. Other clinical and pathologic factors, including patients’ heights, weights, body mass indices, histologic and nuclear grades, ER and PR, and HER2 statuses of primary breast cancer, did not differ significantly between the two groups.

Representative cases are shown in Figures 3 and 4.

**DISCUSSION**

Our results revealed that the mean SUVmax and SUVmean values in normal glandular tissue were significantly different in terms of BPE grade, with the highest values in the marked BPE group and the lowest values in the minimal BPE group. Glucose metabolism in normal breast parenchyma was highest and lowest in the 3rd and 2nd weeks of the menstrual cycle, respectively.

A recent study by Mema et al. [22] reported similar results to our study; mean SUVmax was significantly higher in the high versus low BPE group (1.90 vs. 1.17, \( p < 0.001 \)), and SUVmax values significantly correlated with qualitative and quantitative measurements of BPE on MRI (\( p < 0.001 \), \( r = 0.59 \) and \( r = 0.54 \), respectively). Our results also revealed that SUVmax values were significantly correlated with qualitative measurements of BPE on MRI, but the degree of correlation was higher in the SUVmean compared to SUVmax values (\( r = 0.472 \), \( p < 0.001 \) for SUVmax; \( r = 0.498 \), \( p < 0.001 \) for SUVmean). Mema et al. [22] concluded that the increased risk of breast cancer development in patients with high BPE could be associated with the increased metabolism of normal breast parenchyma, providing a suitable environment for cancer development.

BPE on MRI has been reported as a risk factor for breast cancer development in several studies [12,13,24,25]. In a study by Wu et al. [24], the odds ratio of malignancy was 3.5 per 20% point increases in percent of BPE in multivariate analysis controlling for menopausal status, family history of breast cancer, parenchymal density on mammography, and the amount of fibroglandular tissue on MRI. The odds ratios were similar for three subtracted images scanned at 1 minute 30 seconds, 4 minutes 30 seconds, and 7 minutes 30 seconds af-
Metabolic Activity of Normal Breast Parenchyma in Breast Cancer Patients

In conclusion, the metabolic activity of normal breast parenchyma is highest and lowest in the 3rd and 2nd weeks of the menstrual cycle, respectively, with moderate correlations with BPE on MRI. Metabolic activity tends to be lower than blood flow or vessel permeability in the 4th week of the menstrual cycle.

**CONFLICT OF INTEREST**

The authors declare that they have no competing interests.

**REFERENCES**

1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.
2. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women's health initiative randomized trial. JAMA 2003;289:3243-53.
3. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.
4. Begg CB, Halle RW, Borg A, Malone KE, Concannon P, Thomas DC, et al. Variation of breast cancer risk among BRCA1/2 carriers. JAMA
5. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017;317:2402-16.

6. Wolfe JN, Saftlas AF, Salane M. Mammographic parenchymal patterns and quantitative evaluation of mammographic densities: a case-control study. AJR Am J Roentgenol 1987;148:1087-92.

7. Byrne C, Schairer C, Wolfe J, Paredi N, Salane M, Brinton LA, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 1995;87:1622-9.

8. Saftlas AF, Hoover RN, Brinton LA, Szklm O, Olson DR, Salane M, et al. Mammographic densities and risk of breast cancer. Cancer 1991;67:2833-8.

9. Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB, et al. Mammographic density-a review on the current understanding of its association with breast cancer. Breast Cancer Res Treat 2014;144:479-502.

10. Pike MC, Pearce CL. Mammographic density, MRI background parenchymal enhancement and breast cancer risk. Ann Oncol 2013;24 Suppl 8:viii37-41.

11. Huo CW, Chiew GL, Britt KL, Ingman WV, Henderson MA, Hopper JL, et al. Mammographic density-a review on the current understanding of its association with breast cancer. Cancer 1991;67:2833-8.

12. Donthos BN, Rahbar H, Partridge SC, Korde LA, Lam DL, Scheel JR, et al. Are qualitative assessments of background parenchymal enhancement, amount of fibroglandular tissue on mr images, and mammographic density associated with breast cancer risk? Radiology 2015;276:371-80.

13. King V, Brooks JD, Bernstein JL, Reiner AS, Pike MC, Morris EA. Background parenchymal enhancement at breast MR imaging and breast cancer risk. Radiology 2011;260:50-60.

14. van der Velden BH, Dmitriev I, Loo CE, Pijnappel RM, Gilhuis KG. Association between parenchymal enhancement of the contralateral breast in dynamic contrast-enhanced MR imaging and outcome of patients with unilateral invasive breast cancer. Radiology 2015;276:675-85.

15. Lim Y, Ko ES, Han BK, Ko EY, Choi JS, Lee JE, et al. Background parenchymal enhancement on breast MRI: association with recurrence-free survival in patients with newly diagnosed invasive breast cancer. Breast Cancer Res Treat 2017;163:573-86.

16. Kim SA, Cho N, Ryu EB, Seo M, Bae MS, Chang JM, et al. Background parenchymal signal enhancement ratio at preoperative MR imaging: association with subsequent local recurrence in patients with ductal carcinoma in situ after breast conservation surgery. Radiology 2014;270:699-707.

17. Preibsch H, Wanner L, Bahrs SD, Wietek BM, Siegmann-Luz KC, Oberlecher E, et al. Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response. Eur Radiol 2016;26:1590-6.

18. Choi JS, Ko ES, Ko EY, Han BK, Nam SJ. Background parenchymal enhancement on preoperative magnetic resonance imaging: association with recurrence-free survival in breast cancer patients treated with neoadjuvant chemotherapy. Medicine (Baltimore) 2016;95:e3000.

19. Back JE, Kim SH, Lee AW. Background parenchymal enhancement in breast MRIs of breast cancer patients: impact on tumor size estimation. Eur J Radiol 2014;83:1356-62.

20. Park SY, Kang DK, Kim TH. Does background parenchymal enhancement on MRI affect the rate of positive resection margin in breast cancer patients?. Br J Radiol 2015;88:20140638.

21. Leithner D, Balthzer PA, Magometschnigg HE, Wengert GJ, Karanikas G, Helbich TH, et al. Quantitative assessment of background parenchymal uptake on 18F-FDG PET/CT: correlation with age, background parenchymal enhancement, and amount of fibroglandular tissue on MRI. J Nucl Med 2016;57:1518-22.

22. Mena E, Mango VL, Guo X, Karcich J, Yeh R, Wynn RT, et al. Does breast MRI background parenchymal enhancement indicate metabolic activity? Qualitative and 3D quantitative computer imaging analysis. J Magn Reson Imaging. Epub 2017 Jun 24. https://doi.org/10.1002/jmri.25798

23. Morris EA, Comstock CE, Lee CH, Lehman CD, Ikeda DM, Newstead GM, et al. ACR BI-RADS magnetic resonance imaging. In: ACR BI-RADS Atlas, Breast Imaging Reporting and Data System. Reston: American College of Radiology; 2013. p.124-76.

24. Wu S, Zuley ML, Berg WA, Kurland BE, Jankowitz RC, Sumkin JH, et al. DCE-MRI background parenchymal enhancement quantified from an early versus delayed post-contrast sequence: association with breast cancer presence. Sci Rep 2017;7:2115.

25. Telegrafo M, Rella I, Stabile Ianora AA, Angegelli G, Moschetta M. Breast MRI background parenchymal enhancement (BPE) correlates with the risk of breast cancer. Magn Reson Imaging 2016;34:173-6.

26. Vogel PM, Georgiade NG, Fetter BF, Vogel FS, McCarty KS Jr. The correlation of histologic changes in the human breast with the menstrual cycle. Am J Pathol 1981;104:23-34.

27. Goingt J, Anderson TJ, Batterby S, MacIntyre CC. Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol 1988;130:193-204.

28. Müller-Schimpfle M, Ohmenhaüser K, Stoll P, Dietz K, Claussen CD. Breast MRI background parenchymal enhancement (BPE) correlates with the risk of breast cancer. Radiology 2016;276:371-80.

29. Vogel PM, Georgiade NG, Fetter BF, Vogel FS, McCarty KS Jr. The correlation of histologic changes in the human breast with the menstrual cycle. Am J Pathol 1981;104:23-34.

30. Muller-Chimptle M, Ohmenhaiser K, Stoll P, Dietz K, Claussen CD. Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. Radiology 1997;203:145-9.

31. Kuhl CK, Bieling HB, Gieseke J, Kreft BP, Sommer T, Lutterby G, et al. Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. Radiology 1997;203:137-44.